Mayukh Sukhatme - Dec 23, 2024 Form 4 Insider Report for Roivant Sciences Ltd. (ROIV)

Role: Pres&Chief Investment Officer, Director
Signature: By: /s/ Jo Chen, as Attorney-in-Fact for Mayukh Sukhatme
Stock symbol: ROIV
Transactions as of: Dec 23, 2024
Transactions value $: -$7,229,727
Form type: 4
Date filed: 12/26/2024, 09:00 PM
Previous filing: Dec 20, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ROIV	Common Shares	Options Exercise	$41.6K	+10.8K	+0.06%	$3.85	18.8M	Dec 23, 2024	Direct
transaction	ROIV	Common Shares	Sale	-$130K	-10.8K	-0.06%	$12.00	18.8M	Dec 23, 2024	Direct	F1
transaction	ROIV	Common Shares	Options Exercise	$716K	+186K	+0.99%	$3.85	19M	Dec 24, 2024	Direct
transaction	ROIV	Common Shares	Sale	-$2.23M	-186K	-0.98%	$12.00	18.8M	Dec 24, 2024	Direct	F1
transaction	ROIV	Common Shares	Options Exercise	$2.65M	+689K	+3.66%	$3.85	19.5M	Dec 26, 2024	Direct
transaction	ROIV	Common Shares	Sale	-$8.28M	-689K	-3.53%	$12.01	18.8M	Dec 26, 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ROIV	Stock Option (Right to Buy)	Options Exercise	$0	-10.8K	-0.07%	$0.00	16.1M	Dec 23, 2024	Common Stock	10.8K	$3.85	Direct	F2
transaction	ROIV	Stock Option (Right to Buy)	Options Exercise	$0	-186K	-1.15%	$0.00	15.9M	Dec 24, 2024	Common Stock	186K	$3.85	Direct	F2
transaction	ROIV	Stock Option (Right to Buy)	Options Exercise	$0	-689K	-4.33%	$0.00	15.2M	Dec 26, 2024	Common Stock	689K	$3.85	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
F2	Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).

Content

The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).